Lawsuits Over TDF Drug Injuries Dismissed After California Supreme Court Ruling

The California Supreme Court issued a ruling that effectively ended approximately 24,000 product liability lawsuits filed against pharmaceutical manufacturer Gilead Sciences. The cases were brought by former users of HIV medications containing tenofovir disoproxil fumarate (TDF), a compound found in drugs including Truvada, Viread, Atripla, Complera, and Stribild.

Plaintiffs alleged that Gilead knowingly sold toxic and dangerous versions of these drugs while possessing a safer alternative formulation. The plaintiffs claimed the company possessed knowledge of tenofovir alafenamide fumarate (TAF), an alternative compound believed to reduce the risk of bone problems, kidney damage, and other side effects associated with older TDF formulations. The core allegation was that Gilead deliberately delayed development and commercialization of TAF-based HIV drugs to extend its market monopoly by preventing generic competition as the TDF drug patents approached expiration.

The California court's ruling rejected the plaintiffs' product liability theory, finding that Gilead did not owe a legal duty to develop or market safer drug formulations. This decision effectively terminated the multi-year litigation campaign that had accumulated tens of thousands of individual cases in California state courts, all raising substantially similar claims regarding allegedly delayed development of safer HIV treatments.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.